Table 3 Adjusted1 Hazard Ratio for Overall and Disease-specific Survival
From: Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer
Risk Factors | Overall Survival | Disease-Specific Survival | ||
|---|---|---|---|---|
| Â | HR (95% CI) | HR (95% CI) | ||
| Â | All Histologies N = 237 | SCC N = 215 | All Histologies N = 234 | SCC N = 212 |
p16 Status | Â | Â | Â | Â |
   p16- | 1.2 (0.7-2.2)1 | 0.9 (0.5-1.7) | 1.5 (0.7-3.1)1 | 1.0 (0.5-2.2) |
   p16+ | referent | referent | referent | referent |
p53 Status | Â | Â | Â | Â |
   p53- | referent | referent | referent | referent |
   p53+ | 1.4 (0.9-2.2)1 | 1.3 (0.8-2.2) | 1.9 (1.04-3.4)1 | 1.9 (1.01-3.5) |
HPV Status | Â | Â | Â | Â |
   HPV-HR | referent | referent | referent | referent |
   HPV- | 2.1 (1.1-4.3)1 | 2.6 (1.2-5.3) | 1.6 (0.7-3.7)1 | 2.1 (0.9-4.8) |
p16/p53/HPV Status3 | Â | Â | Â | Â |
   p16+/p53-/HPV-HR | referent | referent | referent | referent |
   p16-/p53-/HPV-HR | NE3 | NE3 | NE3 | NE3 |
   p16+/p53+/HPV-HR | 1.6 (0.4-5.7) | 1.8 (0.5-6.3) | 0.9 (0.2-4.7) | 1.0 (0.2-5.3) |
   p16-/p53+/HPV-HR | 3.2 (0.8-13.4) | 2.8 (0.7-11.5) | 3.9 (0.9-16.9) | 3.4 (0.8-14.9) |
   p16-/p53+/HPV- | 4.1 (1.7-9.9) | 3.7 (1.5-9.0) | 4.0 (1.5-10.7) | 3.7 (1.4-9.9) |
   p16+/p53-/HPV- | 2.9 (0.9-9.1) | 3.6 (1.1-11.1) | 1.7 (0.4-7.3) | 2.2 (0.5-9.2) |
   p16-/p53-/HPV- | 3.1 (1.2-7.9) | 3.2 (1.2-8.2) | 1.9 (0.6-5.7) | 1.9 (0.6-5.9) |
   p16+/p53+/HPV- | 3.4 (1.1-10.3) | 4.6 (1.4-14.5) | 2.9 (0.8-10.3) | 4.6 (1.3-16.1) |
Age2 | 1.03 (1.01-1.05) | 1.04 (1.02-1.1) | 1.03 (1.01-1.05) | 1.04 (1.01-1.1) |
Stage | Â | Â | Â | Â |
   I/II | referent | referent | referent | referent |
   III/IV | 3.1 (1.7-5.9) | 3.1 (1.6-6.0) | 4.6 (1.9-10.9) | 4.5 (1.9-11.0) |